Design Therapeutics (DSGN) Amortizatization of Intangibles (2020 - 2026)
Design Therapeutics (DSGN) reported Amortizatization of Intangibles of $147000.0 for Q1 2026, down 86.13% on a YoY basis from $1.1 million in Q1 2025, and down 71.29% sequentially from $512000.0 in Q4 2025.
Design Therapeutics (DSGN) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
Design Therapeutics (DSGN) has 7 years of Amortizatization of Intangibles data on file, last reported at $147000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles fell 86.13% year-over-year to $147000.0; the trailing twelve-month figure through Mar 2026 stood at $2.3 million (down 57.66% YoY), and the FY2025 full-year result was $3.3 million, down 47.52% from the prior year.
- Amortizatization of Intangibles retreated to $147000.0 in Q1 2026, from $512000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $1.8 million in Q4 2023 to a low of -$19000.0 in Q1 2022.
- A 5-year average of $1.0 million and a median of $1.1 million in 2025 frame the typical range for Amortizatization of Intangibles.
- Across the five-year window, Amortizatization of Intangibles plunged 112.67% in 2022 and soared 6110.53% in 2023, its largest moves.
- Tracing DSGN's Amortizatization of Intangibles over 5 years: stood at $899000.0 in 2022, then soared by 104.23% to $1.8 million in 2023, then dropped by 21.68% to $1.4 million in 2024, then sank by 64.39% to $512000.0 in 2025, then sank by 71.29% to $147000.0 in 2026.
- Business Quant data shows DSGN's Amortizatization of Intangibles at $147000.0 in Q1 2026, $512000.0 in Q4 2025, and $767000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | Design Therapeutics | 735.98 Mn | 513.16 Mn | - | 147,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 147,000.00 |
| Mar 31, 2026 | 147,000.00 |
| Dec 31, 2025 | 512,000.00 |
| Dec 31, 2025 | 512,000.00 |
| Sep 30, 2025 | 767,000.00 |
| Sep 30, 2025 | 767,000.00 |
| Jun 30, 2025 | 914,000.00 |
| Jun 30, 2025 | 914,000.00 |
| Mar 31, 2025 | 1.06 Mn |
| Mar 31, 2025 | 1.06 Mn |
| Dec 31, 2024 | 1.44 Mn |
| Dec 31, 2024 | 1.44 Mn |
| Sep 30, 2024 | 1.46 Mn |
| Sep 30, 2024 | 1.46 Mn |
| Jun 30, 2024 | 1.57 Mn |
| Jun 30, 2024 | 1.57 Mn |
| Mar 31, 2024 | 1.73 Mn |
| Mar 31, 2024 | 1.73 Mn |
| Dec 31, 2023 | 1.84 Mn |
| Dec 31, 2023 | 1.84 Mn |